Clinical Trial Update: To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects [Phase 1]

View source ↗

Summary

This Phase 1 study evaluates the pharmacokinetics and safety of TQ05105 Tablet in hepatic impairment subjects with myelofibrosis, and the trial is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• TQ05105 Tablet

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Myelofibrosis | Phase 1 | Status: RECRUITING